Pulmonary Hypertension and interstitial Lung Disease (2nd Edition)

Description

The first edition of this book, published in 2009, was the only book of its kind dedicated exclusively to the diagnosis and management of pulmonary arterial hypertension (PAH) in patients with interstitial lung disease (ILD). Over the past few years, new diagnostic tests and treatments of pulmonary arterial hypertension have been developed and tested. Diagnostic testing has led to more frequent and specific diagnosis in PAH patients, leading to the more widespread use of effective treatment and improved quality of life and reduction of mortality for PAH patients. Pulmonary Hypertension and Interstitial Lung Disease: A Clinical Guide, Second Edition provides an updated and expanded state-of-the-art overview of the problems seen by physicians in the clinical management of ILDs. The first section of the book discusses general features and includes an overview of clinical features, diagnosis and pathology of ILD. The second part discusses specific disorders such as idiopathic pulmonary fibrosis, sarcoidosis, and hypersensitivity pneumonia. Pulmonary Hypertension and Interstitial Lung Disease, Second Edition is an invaluable resource for all physicians whose practice involves the care and treatment of patients with interstitial lung disease.

Table of Contents

1. Chapter 1: Radiographic Imaging in Interstitial Lung Disease and Pulmonary Hypertension
2. Introduction
3. Pulmonary Hypertension in Interstitial Lung Disease
4. Chest X-ray in Interstitial Lung Disease with Pulmonary Hypertension
5. HRCT in IPF with Pulmonary Hypertension
6. HRCT in NSIP with Pulmonary Hypertension
7. HRCT in Respiratory Bronchiolitis and Interstitial Lung Disease (RB-ILD)
8. HRCT in Cryptogenic Organizing Pneumonia (COP) with Pulmonary Hypertension
9. HRCT in Acute Interstitial Pneumonia (AIP) with Pulmonary Hypertension
10. HRCT in Desquamative Interstitial Pneumonia (DIP)
11. HRCT in Lymphocytic Interstitial Pneumonia (LIP)
12. HRCT and PH in the Complications of ILD
13. IPF and Superimposed Acute Thromboembolic Disease
14. HRCT in Acute Exacerbation of IPF and Pulmonary Hypertension
15. HRCT in Combined Pulmonary Fibrosis and Pulmonary Emphysema (CPFE)
16. Cardiogenic Pulmonary Edema
17. Orphan Lung Diseases and Pulmonary Hypertension
18. Glossary
19. Chapter 2: Invasive Techniques for Diagnosis of PH
20. Introduction
21. Methodological Considerations
22. Measurements and Definitions
23. Resting Hemodynamics and Prognosis in PH
24. PH “Out of Proportion”
25. Interventions During RHC
26. Exercise
27. Fluid Challenge
28. Vasodilator Challenge
29. Conclusion
30. Chapter 3: Pathology of Vascular Changes in Interstitial Lung Diseases
31. Introduction
32. General Considerations
33. Normal Microanatomy of the Pulmonary Circulation
34. Normal Pulmonary Arteries
35. Normal Pulmonary Veins
36. Hemodynamic Consequences
37. Angiogenesis
38. Vascular Remodeling
39. Arterial Remodeling
40. Venous Remodeling
41. Pathology of Vascular Changes in ILDs
42. Evaluation of Vascular Changes in ILDs
43. IPF
44. Vascular Remodeling and Angiogenesis in IPF
45. Angiogenic and Angiostatic Imbalance in IPF
46. Possible Shared Pathogenic Mechanisms between IPF and PH
47. Influence of Angiogenesis/Vascular Remodeling on Pulmonary Fibrogenesis and Vice Versa
48. SSc-Associated ILD
49. Sarcoidosis
50. Vascular Changes in Pulmonary Sarcoidosis
51. Vascular Changes in Sarcoidosis-Associated PH
52. Pulmonary Langerhans Cell Histiocytosis (PLCH)
53. Chapter 4: Treatment of Pulmonary Hypertension in Interstitial Lung Disease
54. Introduction
55. Rationale to Treat
56. Results of Prior Studies
57. Selecting the Appropriate Population to Treat
58. Treatment of Pulmonary Hypertension in Interstitial Lung Disease
59. Treatment of Pulmonary Hypertension in Sarcoidosis
60. Future Directions
61. Conclusion
62. Chapter 5: Lung Transplantation in Interstitial Lung Disease
63. Overview
64. Pretransplant Considerations
65. Timing of Transplant Referral
66. Comorbidities
67. Pulmonary Hypertension
68. Esophageal Dysfunction
69. Contraindications
70. Bridge Therapies to Transplant
71. Operative Considerations
72. Type of Procedure
73. Single versus Double Lung Transplant
74. Posttransplant Considerations
75. Immunosuppression
76. Primary Graft Dysfunction
77. Infection
78. Allograft Dysfunction
79. Lung Function and Exercise Capacity
80. Survival
81. Quality of Life
82. Conclusion
83. Chapter 6: Pulmonary Hypertension in Idiopathic Interstitial Pneumonias
84. Introduction
85. Prevalence
86. Prognostic Significance
87. Diagnosis
88. Pathogenesis of PH in IIP
89. Rarefaction and Angiogenesis
90. Pulmonary Vascular Remodelling
91. Potential Vasoactive Mediators and Growth Factors
92. ET-1
93. VEGF
94. TGF-β
95. PDGF
96. Hypoxia-Related Mechanisms
97. Sleep-Disordered Breathing
98. Left-Sided Heart Disease
99. Thrombosis
100. Treatment of IIP–PH
101. Background
102. Basic Principles of Treatment of PH Associated with IIP
103. Oxygen Therapy
104. Prevent and Treat Exacerbations
105. Recognition and Treatment of Coexistent Co-morbidities
106. Sleep-Discorded Breathing/Nocturnal Desaturation
107. Left Heart Disease
108. Pulmonary Embolism
109. Evidence for the Use of Pulmonary Vasodilators
110. Phosphodiesterase Type-5 Inhibitors (PDE-5)
111. Endothelin Receptor Antagonists
112. Prostanoids
113. Guanylate Cyclase Stimulators
114. Conclusion
115. Chapter 7: Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment
116. Introduction
117. Causes of SAPH
118. Frequency of SAPH
119. Diagnosis of SAPH
120. Treatment
121. Chapter 8: Hypersensitivity Pneumonitis
122. Introduction
123. Pathogenic Mechanisms
124. Clinical Behavior
125. Acute HP
126. Subacute HP
127. Chronic HP
128. Chest Imaging
129. Findings on High-Resolution Computed Tomography (HRCT)
130. Physiologic Abnormalities
131. Hemodynamic Measurements
132. Diagnostic Appraisal and Additional Tools for Difficult Cases
133. Treatment and Prognosis
134. Chapter 9: Interstitial Lung Disease-Associated Pulmonary Hypertension in the Connective Tissue Di
135. Introduction
136. Interstitial Lung Disease in the CTDs
137. CTD-Associated Pulmonary Hypertension
138. Etiopathogenesis
139. Clinical Manifestations
140. Diagnostic Strategy
141. Prognosis
142. Management
143. Lung Transplantation
144. Future Directions
145. Conclusion
146. Chapter 10: Pulmonary Hypertension in Rare Parenchymal Lung Diseases
147. Introduction
148. PH in Pulmonary Langerhans’s Histiocytosis (PLCH-PH)
149. PH in Lymphangioleiomyomatosis (PH-LAM)
150. PH in Neurofibromatosis 1 (PH-NF1)
151. PH in Cystic Fibrosis (PH-CF)
152. Rare Reports of PH in Rare Diseases with ILD Manifestations
153. Conclusion

Editors Biography

Robert P. Baughman, MD University of Cincinnati Medical Center Cincinnati, OH, USA

Roberto G. Carbone, MD Regional Hospital Department of Internal Medicine Aosta, Italy

Steven D. Nathan, MD Inova Heart and Vascular Institute Falls Church, VA, USA